Dave Coulier's Two Cancers: Understanding HPV and Throat Cancer

What he has shared

Variety reported on 4 February 2026 that Dave Coulier, who is 66, said on Good Morning America that he was in remission from tongue cancer. He first shared that diagnosis in December, nearly a year after being treated for stage 3 non-Hodgkin lymphoma.

According to that report, he was diagnosed with p16 squamous carcinoma after doctors noticed something at the base of his tongue during a routine check-up and a PET scan. His doctors told him the tongue cancer was totally unrelated to the lymphoma. He had 35 rounds of radiation, finishing on 31 December. He said in December that he had been told this cancer carried a 90% curability rate.

Those are his own statements and the reporting around them. This page does not add to them, and it does not treat one person's outcome as a forecast for anyone.

What "p16" is doing in that diagnosis

The word most people would expect is HPV, and p16 is how the laboratory gets there.

p16 is a protein. In oropharyngeal cancer, cells overproduce it when high-risk HPV has switched off a control mechanism. NCI's clinical summary lists biopsy and p16 testing as the standard way to assess HPV status in these tumors.

So a report reading p16-positive is, in practice, describing a cancer driven by HPV. Squamous carcinoma is the cell type. NCI notes that most HPV-related cancers are squamous cell carcinomas, because HPV infects the thin flat squamous cells lining these surfaces.

The oropharynx, and why the base of the tongue is hard to catch

The oropharynx is the middle section of the throat, behind the mouth. NCI defines it as sitting between the soft palate above and the hyoid bone below. It divides it into the base of the tongue, the vallecula, the tonsil region, the soft palate, and the back and side walls of the throat.

The base of the tongue is not the part you can stick out. It is the rear third, angled down toward the throat.

NCI describes cancers there as insidious, and gives the anatomical reason: the base of the tongue has no pain fibers. Tumors are often silent until they have grown a great deal.

That is why Coulier's was found on imaging done for something else. It is also why most cases are picked up once lymph nodes are already involved. In one large series NCI cites, the base of the tongue and the tonsil were the two most common primary sites, and 94% of patients had stage III to IVB disease.

Lymph drainage in that area is rich. NCI reports that around 70% or more of people with advanced base-of-tongue cancer have cancer in neck lymph nodes on the same side.

How HPV becomes a throat cancer

NCI's account is straightforward, and it takes a lot of unnecessary shame out of the topic.

Nearly all sexually active people are infected with HPV within months to a few years of becoming sexually active. About half of those infections involve a high-risk type. The immune system usually clears them within a year or two.

Cancer comes from the few that persist. When a high-risk infection lasts for many years, it can drive cell changes that slowly turn precancerous and then cancerous.

NCI states that 70% of oropharyngeal cancer is caused by HPV. It attributes the rising rate of this cancer to the rise in HPV-associated cases. Men are almost three times as likely as women to develop it.

Our page on HPV and cancer covers the other five cancers HPV causes.

Why HPV status changes the outlook

This is the part that explains why an oncologist might sound relatively hopeful about a throat cancer.

NCI lists three prognostic factors for oropharyngeal cancer: HPV status, a smoking history of 10 or more pack-years, and tumor and node stage. It then sets out a risk grouping drawn from a randomized trial.

People who were HPV-positive, had 10 or fewer pack-years of smoking, and had limited nodal disease fell into the low-risk group. Their three-year overall survival rate was 93%. The intermediate group sat at 70.8%. The high-risk group, HPV-negative with more than 10 pack-years of smoking, was 46.2%.

Same site, same cell type, and outcomes that differ by half depending on cause and smoking history.

Those are trial-population figures for groups of people, not a prediction for any one person.

When to get checked

There is no screening test for oropharyngeal cancer, so this rests on symptoms that persist.

NCI's list for advanced base-of-tongue cancer:

• Pain
• Trouble swallowing, called dysphagia
• Weight loss
• Ear pain on one side with a normal-looking ear, which can be referred pain from the throat
• Difficulty opening the mouth fully
• A lump in the neck

The one-sided ear ache with a healthy ear is the item clinicians most want people to know. So is a painless neck lump that has not gone in three weeks. Either can be the first sign of something at the back of the tongue.

What this does not mean

Two cancers in one person, close together, does not mean one caused the other. Coulier said his doctors told him they were unrelated, and nothing in the reporting suggests otherwise.

A 90% figure quoted by a patient in an interview is not a staging statement. It reflects what he was told about his own case, which took in his HPV status, his stage, and his smoking history.

Radiation for head and neck cancer is also demanding. Effects on swallowing, taste and saliva can last well past treatment. Our pages on radiation therapy and head and neck cancer cover what that involves.

For 2026 the American Cancer Society projects about 60,480 new oral cavity and pharynx cancer diagnoses in the United States and about 13,150 deaths; SEER, the federal cancer surveillance program, is where those appear. SEER's own measurement of five-year relative survival is 69.9% across all stages. That figure pools many different sites and causes together, and it describes a population rather than a person.

Sources

• Variety: Dave Coulier in Remission From Tongue Cancer One Year After Beating Stage 3 Lymphoma
• NCI PDQ: Oropharyngeal Cancer Treatment (Health Professional Version)
• NCI: HPV and Cancer
• NCI SEER Stat Facts: Oral Cavity and Pharynx Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.